Cite
HARVARD Citation
Fehlings, M. et al. (n.d.). Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in non-small cell lung carcinoma patients responding to atezolizumab treatment. European journal of cancer. pp. S2-S3. [Online].